Vaxcyte Inc Ordinary Shares PCVX
News
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte to Participate in Upcoming Investor Conferences
Vaccine stocks slide as FDA official links COVID vaccines and heart conditions in young men
Vaxcyte to Partner with Thermo Fisher to Increase Vaccine Production in U.S.


